NCT00358956

A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

A Phase II, Open-Label Study To Assess The Efficacy and Tolerability of ZD6474 (ZACTIMA™ ) 100 mg Monotherapy In Subjects With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 19 (actual)
• Sponsor: Genzyme, a Sanofi Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This will be a Phase II, open label study to establish the effect of once-daily oral doses of ZD6474 100mg in subjects with locally advanced or metastatic hereditary medullary thyroid cancer in whom no standard therapeutic option is available.

Conditions

• Thyroid Cancer

Interventions

Type	Name	Description
DRUG	ZD6474 (vandetanib)	100 mg once daily oral tablet

Timeline

• Start date: 2006-08-01
• Primary completion: 2008-01-01
• Completion: 2014-05-01
• First posted: 2006-08-01
• Last updated: 2017-01-30
• Results posted: 2012-08-31

Locations

9 sites across 8 countries: United States, Australia, Canada, Italy, Netherlands, Romania, Spain, Switzerland